bazedoxifene BZA-20 — Competitive Intelligence Brief

bazedoxifene BZA-20 (bazedoxifene BZA-20) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor modulator (SERM). Area: Osteoporosis.

phase 3 Selective estrogen receptor modulator (SERM) Estrogen receptor beta (ERβ) Osteoporosis Small molecule

Target snapshot

bazedoxifene BZA-20 (bazedoxifene BZA-20) — Wyeth is now a wholly owned subsidiary of Pfizer. Bazedoxifene acts as a selective estrogen receptor modulator (SERM) with agonist activity on the estrogen receptor beta and antagonist activity on the estrogen receptor alpha.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bazedoxifene BZA-20 TARGET	bazedoxifene BZA-20	Wyeth is now a wholly owned subsidiary of Pfizer	phase 3	Selective estrogen receptor modulator (SERM)	Estrogen receptor beta (ERβ)
High Dose Clomiphencitrat	High Dose Clomiphencitrat	University Hospital, Basel, Switzerland	marketed	Selective estrogen receptor modulator (SERM)	Estrogen receptor (ER-α and ER-β)
fenofibrate and tibolone	fenofibrate and tibolone	Keogh Institute for Medical Research	marketed	Fibrate + Selective Estrogen Receptor Modulator (SERM)	PPAR-α (fenofibrate); Estrogen receptor, progesterone receptor, androgen receptor (tibolone)
Metformin plus clomiphene citrate	Metformin plus clomiphene citrate	University Magna Graecia	marketed	Combination therapy: biguanide + selective estrogen receptor modulator (SERM)	Insulin signaling pathway (metformin); estrogen receptor (clomiphene citrate)
tamoxifen citrate (Tamoxifen)	tamoxifen citrate (Tamoxifen)	H. Lee Moffitt Cancer Center and Research Institute	marketed	Selective estrogen receptor modulator (SERM)	Estrogen receptor alpha (ERα)
Tamoxifen (open label)	Tamoxifen (open label)	Oregon Health and Science University	marketed	Selective estrogen receptor modulator (SERM)	Estrogen receptor alpha (ERα)
Low Dose Clomiphencitrat	Low Dose Clomiphencitrat	University Hospital, Basel, Switzerland	marketed	Selective estrogen receptor modulator (SERM)	Estrogen receptor (ER-α and ER-β)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor modulator (SERM) class)

1. University Hospital, Basel, Switzerland · 2 drugs in this class
2. AstraZeneca · 2 drugs in this class
3. Estetra · 1 drug in this class
4. Fundació Privada Eugin · 1 drug in this class
5. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class
6. National Taiwan University Hospital · 1 drug in this class
7. Oregon Health and Science University · 1 drug in this class
8. Samsung Medical Center · 1 drug in this class
9. Shandong Suncadia Medicine Co., Ltd. · 1 drug in this class
10. Sheba Medical Center · 1 drug in this class